That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

in 2025 that could impact how you pay for your medications — and how much you pay. Here’s what you need to know as we kick off the new year. 1. Out-of-pocket drug costs will be capped at $2,000 The ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation system in a larger group of patients with atrial fibrillation.

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.